Merck & Co at ASCO 2026: Keytruda Data and Pipeline Signals Ahead of Patent Expiry
This article was created with the help of artificial intelligence.
Key Takeaways
- Merck & Co presented new data at ASCO 2026 on Keytruda, its PD-1 inhibitor for various cancers, in solid tumors.
- The company is developing personalized mRNA cancer vaccines with Moderna to offset Keytruda's upcoming patent expiry.
- Moderna shares rose 5.1 percent following the presentation of positive long-term data on the mRNA cancer vaccines.
- Mergers and acquisitions in the biopharm industry reached a volume of 106 billion US dollars across 201 deals by early June 2026.
- The NYSE Healthcare Index rose 3.2 percent on June 4, 2026, driven by interest in oncology innovations and the ongoing acquisition wave.
Merck & Co presented new data on June 5, 2026 at the ASCO conference (American Society of Clinical Oncology) on its immuno-oncology blockbuster Keytruda for solid tumors. Keytruda, a PD-1 inhibitor for treating various cancers, remains a central revenue driver for the company, while the pipeline shows additional candidates designed to prepare for the upcoming patent expiry of the drug.
Pipeline Development in the Shadow of Keytruda's Patent Expiry
The data presented at ASCO 2026 underscore Keytruda's continued strength in solid tumors—a group of cancers consisting of solid tissue masses, as opposed to blood cancers. At the same time, the pipeline candidates shown signal strategies by which Merck & Co aims to close the revenue gap after Keytruda's patent protection expires.
The company is working with biotechnology company Moderna on personalized mRNA cancer vaccines. On June 5, 2026, both partners presented positive long-term data on this technology, which is based on individual tumor material from patients and is designed to specifically activate the immune system against cancer cells. Moderna's stock subsequently rose 5.1 percent.
Consolidation Wave in the Pharmaceutical Industry
The presentation at the ASCO conference comes during a phase of intense consolidation in the biopharm industry. According to CNBC, mergers and acquisitions in the sector reached a volume of 106 billion US dollars across 201 deals by early June 2026. This puts the industry on track for the strongest full year since the pre-crisis peak in 2019. Leading players in this acquisition wave include, alongside Merck, Gilead and Eli Lilly.
Eli Lilly argues that even without its metabolic business—which covers medicines for diabetes and obesity—the company would rank among the fastest-growing pharmaceutical companies in the industry. The immunology, oncology and neuroscience segments drive additional growth.
Positive Sentiment in the Healthcare Sector
The NYSE Healthcare Index rose 3.2 percent on June 4, 2026 in late afternoon trading. The positive development in the healthcare sector reflects interest in innovations in oncology and the momentum of the ongoing acquisition wave.
Merck & Co faces the challenge of offsetting revenue declines from Keytruda's patent expiry through a diversified pipeline. The data presented at ASCO 2026 and the partnership with Moderna show approaches to how the company intends to manage this transition.